A Study of the Safety, Dosing, and Delivery of NEO100 in Patients with Pediatric Brain Tumors
Status:
NOT_YET_RECRUITING
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
This is an open label, Phase 1b safety, dose-finding, brain tumor delivery, and pharmacokinetics study of intranasal NEO100 in patients with pediatric-type diffuse high grade gliomas. Patients will receive IN NEO100 that will follow a dose titration design, followed by a standard dose escalation design to establish safety. Brain tumor delivery of NEO100 will be confirmed in each disease sub-type by surgical resection/needle biopsy only if clinically indicated and scheduled for clinical purposes and testing with residual tissue for NEO100 and the major metabolite of NEO100 (Perillic Acid).